This decision would reverse a 2023 ban that resulted in the removal of 14 peptides from a list of products that the FDA allowed compounding pharmacies to produce.
Multiple brokerages cut their price target on the stock after Doximity reported a fall in third-quarter earnings and a soft fourth-quarter revenue outlook.